Ivytan AB, which is indirectly owned by EQT and Lyftet Holding, has made a cash offer for Swedish biotechnology firm Q-Med valuing the business at SEK 3.9bn. The bid is priced at SEK 39 per Q-Med share - a 24% premium to the closing price on 31 October.
Economic Secretary Richard Fuller spoke about the industry’s role in the government’s growth plan
Sponsor transactions in Europe surged to an all-time high with TMT and the UK leading the way
Acquisition of footfall data analytics group will expand MRI Software’s retail solutions offering
GP sells minority stake after less than three years invested in the IT managed services provider